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Abstract
Hepatitis B virus (HBV) DNA is vulnerable to editing by human cytidine deaminases of the APOBEC3 (A3A-H) family albeit to
much lower levels than HIV cDNA. We have analyzed and compared HBV editing by all seven enzymes in a quail cell line that
does not produce any endogenous DNA cytidine deaminase activity. Using 3DPCR it was possible to show that all but A3DE
were able to deaminate HBV DNA at levels from 10
22 to 10
25 in vitro, with A3A proving to be the most efficient editor. The
amino terminal domain of A3G alone was completely devoid of deaminase activity to within the sensitivity of 3DPCR
(,10
24 to 10
25). Detailed analysis of the dinucleotide editing context showed that only A3G and A3H have strong
preferences, notably CpC and TpC. A phylogenic analysis of A3 exons revealed that A3G is in fact a chimera with the first
two exons being derived from the A3F gene. This might allow co-expression of the two genes that are able to restrict HIV-
1Dvif efficiently.
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Introduction
The human APOBEC3 locus on chromosome 22q13.1 encodes
at least seven genes encoding cytidine deaminases with single
stranded DNA substrate specificity [1]. While their precise cellular
roles remain to be defined, human APOBEC3F and 3G (A3F and
A3G) are so active on nascent lentiviral cDNA that these
retroviruses have evolved a discrete gene product, the Vif protein,
to counter their otherwise devastating effects [2–9]. At much
reduced frequencies, human APOBEC3 (A3) enzymes can
hyperedit HBV genomes as well as those of classical retroviruses
such as spumaviruses and human T cell leukaemia virus type 1 in
vitro [10–15]. Other A3 members restrict the transposition of the
LINEs and Alu retroelements when over-expressed in transfection
assays [16–21]. The expanded 7 gene A3 locus is, for the moment,
a singular feature of macaque, chimpanzee and human genomes.
For the rodent, pig, cattle, cat, dog and horse genomes there are
from 1 to 6 APOBEC3 homologues, some of which can be
coupled by intergenic splicing [22–24].
Three APOBEC3 enzymes (A3A, A3C & A3H) encode a
cytidine deaminase domain (CDD) containing a zinc finger motif,
while the remaining four (A3B, A3DE, A3F and A3G) encode two
CDDs. All CDDs are characterized by the highly conserved
HXEXnPCX2–4C motif that chelates the zinc atom. The glutamic
acid residue (E) is considered to potentiate a water molecule that
acts as the nucleophile in the oxidation of the C4 amino-group
[25–28]. Despite this hallmark, not all CDDs bearing this motif
are active as judged by phenotypic assays [29]. Exchanging CDDs
between A3F and A3G, as well as mutational analyses, have shown
that cytidine deaminase activity essentially resides within the
second, or carboxy-terminal domain, or CDD2 [29–31]. A recent
study has shown that both CDD1 and CDD2 of the arteriodactyl
APOBEC3F and A3G are functional [22].
Despite many reports of APOBEC editing of viral genomes in
experimental systems, only for the lentiviruses, Friend murine
leukaemia virus and hepatitis B virus (HBV) have hyperedited
genomes been described in vivo [12,32,33]. The unique in vivo
HTLV-1 sequence is singular in that it was derived from a
squirrel monkey, a New World monkey, experimentally infected
by HTLV-1 [34]. At the experimental level, phenotypic assays
have been used with great success to identify the effects of
APOBEC3 editing on HIV and spumaviruses, although this
does not preclude low levels of editing because retrovirus
mutation rates are 10–50 fold lower than the error threshold
[35–37]. In addition, as phenotypic effects have been described
in the absence of apparent editing it is not always possible to
separate the two components by phenotypic assays [38,39].
3DPCR is a method that allows selective amplification of
APOBEC edited DNA via modulation of the PCR denaturing
temperature [40]. Using this method we have shown that A3B,
A3C, A3F and A3G are able to edit a few percent of de novo
produced HBV genomes in vitro [14,41,42]. In vivo the method
was capable of detecting edited HBV genomes at frequencies of
,10
24 [14,42].
We set out to explore and compare the impact of all seven
human APOBEC3 deaminases on the HBV genome. With the
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4277sensitivity of 3DPCR it should be possible to identify low levels of
editing that might not be readily picked up in phenotypic assays.
Using the quail cell line QT6 that does not generate any
endogenous editing background, it is shown that 6/7 APOBEC3
enzymes can deaminate a small fraction of hyperedited HBV
genomes in vitro. CDD1 of A3G is totally devoid of deaminase
activity to within the sensitivity of 3DPCR (,10
24). Careful
phylogenetic analysis revealed that APOBEC3G is a chimera with
the first two exons coming from APOBEC3F.
Results
HBV editing by monodomain A3A and A3H
3DPCR is so sensitive that it can amplify heavily APOBEC3
edited HIVDvif genomes even from a permissive cell line such as
293T [40]. It was presumed that this resulted from clonal
heterogeneity whereby a small fraction of cells are expressing high
levels of A3F/G. This phenomenon has been encountered for
some other cell lines, such as Huh7 (not shown). To overcome this
problem we screened a number of avian cell lines because the
avian genome does not encode APOBEC1 or APOBEC3
homologues [43]. By contrast, it encodes a single copy of AID
and APOBEC2. The quail muscle fibroblast cell line QT6 was
chosen for it is readily transfectable.
QT6 cells were transfected with the infectious molecular clone
of HBV, pCayw, in the presence or absence of A3A and A3H
expression plasmids, the two A3 genes not examined in our
previous study [14]. Seventy-two hours post-transfection, super-
natant virus was harvested and treated with DNaseI. By
decreasing the denaturation temperature (Td) it was shown that
,90uC was the minimal temperature allowing amplification of
HBV infection alone (Figure 1A). By contrast, 3DPCR could
recover HBV DNA from the A3A and A3H co-transfections at
temperatures as low as 82.3 and 87.1uC respectively.
The 3DPCR products from the Td=88.4uC amplification were
cloned and up to 60 clones sequenced per sample. A complete
collection of hypermutated sequences is available in Figures S1.
The A3A and A3H enzymes were able to extensively deaminate
HBV DNA (Figure 1B). Both DNA strands were heavily edited
with mean editing frequencies of 20.5% and 40.1% for A3A on the
minus and plus strands respectively, and 6.2% and 11.7% for
A3H. All sequences were unique indicating that they represented
independent molecular events. Indeed, the degree of A3A editing
was among the most extensive we have observed using HBV– up
to 95% of target C residues were edited whether they be on the
plus of minus strands (Figure S1).
3DPCR products from the last positive amplification
(Td=90.1uC, Figure 1A) for the HBV alone control were also
cloned and sequenced. No hypermutated sequences were
identified at all indicating that the QT6 cell line did not generate
a background editing signal (Figure 1C). To confirm this, a
HIVDvif molecular clone was transfected into QT6 cells and the
resulting progeny used to infect the CEMX174 cell line. A 3DPCR
cloning and sequencing analysis failed to identify any viral
hypermutants (not shown), supporting the conclusion that the
QT6 cell line does not generate any background signal.
Uniquely the C-domain of APOBEC3G is active
Although the literature indicates that the amino-terminal
domain of A3G is without editing activity [30,31], this doesn’t
formally preclude a weak-editing activity. As 3DPCR has a greater
dynamic range compared to phenotypic assays, 4 logs compared to
#1.3 logs, we addressed the question of the activity of A3G CDD1
and CDD2 by two approaches. Individual A3G N- and C-
Figure 1. Monodomain A3A and A3H can hyperedit HBV DNA. A) 3DPCR amplification of HBV DNA from on A3A and A3H/pCayw co-
transfections of QT6 using a 12uC gradient across the heating block. M denotes molecular weight markers, while pv refers to the empty expression
vector. Primer-dimers represent the low molecular weight band. B) Mutation matrices compared to the plus strand as reference where n indicates the
number of bases sequenced. C) Mutation matrix for the pCayw plus plasmid vector control.
doi:10.1371/journal.pone.0004277.g001
Genetic Editing of HBV Genome
PLoS ONE | www.plosone.org 2 January 2009 | Volume 4 | Issue 1 | e4277terminal domains (CDD1 and CDD2 respectively) genes were
made by deletion of exons 5–7 and 2–4 respectively compared to
the parental molecule generating A3Gn and A3Gc respectively
(Figure 2A). These constructs differ subtly to others [30,31,44] in
that the core exons 2–4 or 5–7 are always surrounded by exons 1
and 8. Following transfection of HeLa cells the stability of the
A3Gn and A3Gc was analyzed by immunofluorescence micros-
copy using FITC-labelled anti-V5 antibodies. Both constructs
were as stable as the parental A3G. Although A3Gn showed a
somewhat greater nuclear distribution compared to A3G
(Figure 2B), a substantial fraction was in cytoplasm, which is
where HBV capsid assembly occurs.
QT6 cells were transfected by pCayw in the presence or
absence of the different expression plasmids (A3G, A3Gn, A3Gc).
Seventy-two hours post-transfection, virus was harvested and
treated with DNaseI. At 90.4uC it was possible to amplify the
complete HBV segment alone (Figure 3A). At 89.2uC lower
molecular weight bands were found for the negative control and
A3Gn (D, Figure 3A), however cloning and sequencing revealed
that these sequences contained internal deletions and no CRT
transitions. By contrast, DNA was recovered between 87.9–89.2uC
for the A3Gc transfection and 85.9–89.2uC for the A3G control
(*, Figure 3A).
Cloning and sequencing of the 3DPCR products confirmed that
these sequences were indeed hypermutated (Figure 3B, Figure S1).
The average editing efficiencies for genomes recovered at the same
denaturation temperature (89.2uC) were comparable for A3G
(GRA 14.9%; CRT 21.7%) and A3Gc (GRA 9.5%; CRT
22.6%) indicating that the carboxy-terminal domain alone
contains the editing function. To see whether the protocol could
pick up differing degrees of editing a titration was performed using
A3G. As can be seen form Figure 3C, the degree of editing is in
proportion to the mean A3G plasmid concentration. Accordingly,
it may be presumed that the 3DPCR products recovered for A3G
down to 85.9uC are even more hypermutated.
To explore the hypothesis that CDD1 of A3G was slightly active
uniquely in the presence of CDD2, a C291S mutant of A3G was
used [15]. Cysteine 291 is one of the residues that chelates the zinc
atom in CDD2 and is essential to the activity of all A3 enzymes
tested to date. HBV+A3GC291S were transfected into QT6 cells
and 3DPCR performed on supernatant virus. As can be seen from
Figure 4A no products were recovered at the restrictive
temperature of 88uC. Products recovered at 95uC amplifications
were cloned and sequenced. No excess of GCRAT substitutions
was noted compared to controls (Figure 4B).
Among all human APOBEC3 molecules, CDD1 of A3G is
unique in that the alanine residue in the highly conserved
HAEXnPCX2C motif is substituted by proline, a feature
characteristic of the primate A3G lineage back to macaque and
baboons [45]. Given the profound changes a proline residue can
have on protein folding, a PRA substitution was engineered into
codon 66 of the A3Gn and A3GC291S constructs. This P66A
substitution failed to recover any deaminase activity in either a
mono- of double domain construct (A3GnP66A and A3GP66A/C291S,
Figure 4).
Comparable A3G and A3Gc hot and cold spots
The editing frequencies of all 45 cytidine targets in minus strand
HBV DNA for A3G and A3Gc in the QT6 derived experiments
were compared and found to be highly correlated (Figure 5A, B),
again indicating that editing specificity resided in CDD2. In order
to see if the cell line used in the transfection essay could influence
the site specific editing frequencies, A3G and A3Gc editing of
HBV was compared in both cell lines QT6 and Huh7. Site specific
editing frequencies were highly correlated between the two cell
lines for both APOBEC3 constructs (Figure 5C, D) indicating that
Figure 2. Monodomain variants of A3G are stably expressed. A) Boxes denote each of the eight exons; the shaded 6
th exon harbours the zinc
finger motif, HAEXnPCX2C. Shaded exon 3 encodes the singular HPEXnPCX2C variant. The V5 tag is shown as a black box. B) Confocal
immunofluorescence of the three constructs expressed in QT6 cells. DAPI stained cells are on the right, V5 tagged constructs were revealed with x-
labelled monoclonal to the V5 tag (centre), while the merged photos are given to the right.
doi:10.1371/journal.pone.0004277.g002
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temperature across the heating block. M denotes molecular weight markers, pv the empty expression vector, the white asterisks denote hyperedited
HBV DNA, while the white triangles indicate PCR products containing internal deletions (confirmed by sequencing of cloned products). B) Mutation
matrices for A3G and A3Gc on QT6 cells where n indicates the number of bases sequenced. C) The inter-conversion of GRA is related to the
concentration of A3G co-transfected.
doi:10.1371/journal.pone.0004277.g003
Figure 4. Proline 66 is not responsible for the inactive N-terminal Zn finger domain of A3G. A) PCR amplification of HBV DNA from a
variety of co-transfection experiments at 95uC and the restrictive temperature of 88uC. M denotes molecular weight markers; C-, amplification control
without DNA; C+, pCayw alone; pv the empty expression vector as negative control; A2, APOBEC2 as another negative control. Primer-dimers
represent the low molecular weight band. B) Mutational analysis of the cloned 95uC PCR products and those of the positive A3G control at 88uC.
doi:10.1371/journal.pone.0004277.g004
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process, which suggests that editing occurs independently of any
human protein partner.
To estimate the frequency of editing, limiting dilution of first
round PCR products was performed at 95uC and the restricting






(data not shown). The values are lower limits in that not all the
cells were doubly transfected by pCayw and the A3 expression
vector. The results show that the A3Gn domain increases the
efficiency of A3G editing, while A3A turns out to be particularly
efficient (Figures 1A and 3A).
Dinucleotide context of HBV editing by six A3s
As there was no difference between site specific A3G editing of
HBV in the QT6 and Huh7 cell lines, the dinucleotide contexts for
GRA hypermutants can be compared using data sets for A3A and
A3H derived from QT6 and A3B, A3C, A3F ad A3G derived
from Huh7. As mentioned above, we were unable to recover any
A3DE hyperedited HBV genomes. In view of the general excess of
GRA hypermutants over CRT hypermutants, only the former,
which reflect editing of the minus strand were considered.
Sequences with .80% of cytidine residues edited were excluded
from the analysis in order not to mask any dinucleotide
preferences. Obviously, the greater the degree of editing, the
more the observed and expected dinucleotide frequencies
converge. Three distinct patterns were apparent. A3G showed a
strong and significant preference for CpC while A3H showed a
predilection for TpC (Figure 6A). Both showed a strong aversion
for GpC and ApC. The remaining four A3s showed weaker
dinucleotide biases with A3F even showing a slight, but significant
bias in favour of GpC.
The lack of any strong preference for TpC by A3F was
surprising as it is a frequent finding in the HIV-1 literature
[4,8,46–48]. In view of this, we generated comparable hyperedited
data sets for HIVDvif and the same 6 A3 constructs co-transfected
into QT6 cells. Supernatant HIV was then used to infect
CEMX174 cell line. DNA was recovered after 18 h and 3DPCR
performed on a region corresponding to the hypervariable V1V2
regions of env, the restrictive temperature being 78uC (Figure 7A).
3DPCR products amplified at 78uC were cloned and sequenced.
Large numbers of hypermutants were obtained all with GRA
mutation frequencies .100 in excess of the control (Figure 7B,
Figure S2). The dinucleotide frequencies associated with deami-
nation on the minus strand (GRA on the plus strand) were
analyzed in a comparable manner to the HBV hypermutants, that
is those with .80% editing were eliminated from Figure 6B. Five
of the six A3s showed a strong and significant preference for TpC,
Figure 5. Human A3G and A3Gc hot and cold spots are highly correlated. A) Individual editing frequencies across the minus strand target
cytidine residues for A3G and A3Gc co-transfections of Huh7 cells. These represent the fraction of A3 edited sequences bearing an edited C at a given
position. B–D) Highly correlated site-specific editing frequencies for A3G, A3Gc/HBV co-transfections of QT6 and Huh7 cells. The site-specific editing
frequencies calculated for a given data set are correlated with the site-specific editing frequencies from another data set at the level of each C
residue. The identities of the data sets are given on the x and y-axes. Least-mean squared fits to the data are also given.
doi:10.1371/journal.pone.0004277.g005
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dinucleotide preferences may result from the presence of hot spots
within a target sequence (Figure 6B). This time, A3F showed an
aversion for GpC, unlike its behaviour on a HBV template
(Figure 6A). Nonetheless, the preference of A3G for CpC and
A3H for TpC remained.
Human A3C showed the least polarized dinucleotide editing
preference on either an HBV of HIV template. The A3C sequence
is unique in encoding a serine at position 188 as opposed to an
isoleucine residue conserved among all other A3 deaminases,
APOBEC2, AID and even APOBEC1 [1]. A S188I mutant of the
A3C-V5 tagged construct was generated and found to deaminate
HBV in an indistinguishable manner (frequency, dinucleotide
context) compared to the parental sequence without (data not
shown).
Exon based phylogenies for A3s
The modular nature of the human A3s as well as extant
phylogenic studies have shown that recombination can occur
between CDD1 and 2 [49]. As the exon/intron structures for
CDD1 and CDD2 are strictly comparable there is the possibility of
recombination between exons within CDDs. An exon-based
phylogenic analysis showed that the mainly non-coding exons 1
and 8 are, perhaps not surprisingly, fixing mutations faster than
the coding exons 2+5, 3+6 and 4+7, which themselves showed a
generally congruent topology (Figure 8). The obvious exception is
A3G shown in red. Here, exons 1+2 strongly cluster with those of
A3F. As A3F exons 1, 2, 3 and 4 always cluster with those of A3B
and A3DE it would appear that A3G exon 2 is anomalous. Indeed
the coding regions of the first two exons of A3F and A3G differ by
1 base (0.6%, or a single amino acid residue D,2%) while exons 3
and 4 differ by 121 nucleotides (,30%, or 62 amino acid residues,
D,47%) and 2 indels. The 59 breakpoint may map as far as 6.5 kb
upstream of exon 1 (not shown). This event seems to exist as far
back as the Macaca and Cercopithicus monkey lineages (see
Supplementary table 3 in [50]).
Discussion
HBV is sensitive to low frequency editing by 6/7 human
APOBEC3 cytidine deaminases. The finding of A3A hyperedited
HBV genomes is novel and contrasts with a negative report [51].
Those for A3H confirm a recent study [24] and show that all the
monodomain A3 enzymes are able to edit HBV and HIV cDNA.
Indeed, A3A and A3H are some of the most efficient cytidine
deaminases that we have worked with [24]. As the hypermutant
frequencies were in the ,10
22 to 10
25 range, deamination may
represent an insufficient selection pressure to cause the virus to
adapt, unlike the lentiviruses that evolved a vif gene. While
APOBEC3s can be found in the viral HBcAg capsid [14,15],
packaging is inefficient, certainly with respect to the HIV-1Dvif/
A3G as reference. This follows from a consideration of the
intravirion enzyme concentration: the inner HBcAg core volume is
,9 zl [52]. Ignoring the excluded volume due to the HBV
genome, a single molecule of any packaged A3 deaminase
translates into [A3].200 mM. Given that A3G hyperediting of
ssDNA (fCRT,0.2, [53]) was observed in vitro with a enzyme
concentration of ,2 mM, once even a single molecule is packaged
within the HBcAg capsid, hyperediting is inevitable. Accordingly,
packaging must be inefficient.
A similar argument goes for HIV where the core volume is ,90
zl [54]. Ignoring the excluded volume of 2 genomic RNAs, one
molecule of A3G translates into an intravirion [A3G].18 mM. As
Pathak et al. estimated that on average there are 7 A3G molecules
Figure 6. Cytidine deamination dinucleotide context varies as a function of the target sequence. A) Cytidine editing of the minus DNA
strand of HBV by six A3s, the horizontal line indicating the expected values based on the sequence composition of the target. B) Cytidine editing of
the minus DNA strand of HIV by six A3s, the horizontal line indicating the expected values based on the sequence composition of the target. Asterisks
denote statistically significant deviations from the expected value (p,0.001).
doi:10.1371/journal.pone.0004277.g006
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the physiological concentration is [A3G].130 mM. Unlike HBV,
A3F and A3G are efficiently packaged by a HIVDvif virus
meaning that hypermutants may be identified without recourse to
3DPCR.
Genetic editing of HBV is a feature of both the mono- and
double CDD APOBEC3s. CDD1 of A3G is devoid of any cytidine
deaminase activity (Figure 2) down to the 10
24 to 10
25 detection
level characteristic of 3DPCR {Suspene, 2005 #332; Susp,} and
supports the conclusions based on phenotypic analyses in vitro or in
a mouse model [33]. This feature is not conferred by the
evolutionarily conserved substitution of alanine 66 for proline
(Figure 4). Given that CDD2 alone contains the same editing
specificity as the parental A3G molecule, the role/function of
CDD1 remains elusive. Nonetheless, A3G edits HBV cDNA at a
higher frequency compared to A3Gc, an observation that
concords with a higher editing processivity [56], both demonstrate
that CDD1 modulates the function of CDD2. The conservation of
the HXEXnPCX2–4C motif in CDD1 in the absence of
demonstrable deamination remains a puzzle.
That six A3 enzymes expressed in QT6 cells are functional
suggests that they do not require human protein partners, unless of
course it was a highly conserved protein between humans and
birds. This conclusion is echoed by in vitro experiments where
hyperedited DNA was recovered reactions using ssDNA and
baculovirus produced A3G [53], while neo-synthesized A3G in
low molecular weight form, as opposed to that in a high molecular
weight complex, is active on HIV [57,58]. In addition, when
expressed in E. coli hA1, A3G and human AID behave as mutators
generating CRT transitions [2,59]. Taken together, these findings
indicate that A3 enzymes alone are sufficient to undertake
hyperdeamination.
When editing HBV cDNA, only A3G (double domain) and
A3H (mono-domain) showed any strong dinucleotide specificity
(Figure 6A). By contrast the HIV/A3 literature describes A3F as
having a bias for the TpC dinucleotide (Figure 6B and [4,8,46–
48]). The dinucleotide composition of the minus strand of the
HBV segment analysed is 20.5% TpC, 31.9% CpC, 25.0% GpC
and 22.7% ApC. By comparison, that for the HIV minus strand is
even more polarized with 38% TpC, 16% CpC, 18% GpC and
28% ApC. It is possible that the HIV locus, with a greater
proportion of TpC encodes a few hotspots allowing A3A, A3B,
A3F and A3G editing at this dinucleotide to become significant.
The mammalian APOBEC3 locus has undergone expansion
presumably from a single gene. The presence of 1–6 APOBEC3
genes among rodent, carnivore and perissodactyl lineages,
comprising both mono- and double domain molecules, all point
towards extensive gene conversion [60,61]. Given that exon/
intron structures are highly comparable among A3 genes there was
the possibility of recombination between exons. From a phylogenic
consideration of the different exons it would appear that A3G is a
chimera of at least three different segments (exons 1+2, exons 3+4
and exons 5–8; Figure 8).
The ensemble of the A3 phylogenic trees can be resumed in a
schematic form where colour reflects the deep phylogenic
clustering into three or four groups (Figure 9). Other recombina-
tion events are evident, for example, i) the A3A first exon stands
out by coding for 10 distinct residues as opposed to 6 highly
conserved residues for A3B-G; ii) A3H is unusual in that the first
exon is non-coding (see NM_181773); iii) it could be argued that
A3C arose from a duplicated A3DE or A3F gene with subsequent
deletion of exons 2–4; iv) the discordant arborescence of A3A,
A3B and A3G in exons 6 and 7, all of which are supported by
good bootstrap values, is tell tale. If true, the latter example would
mean that A3G has an even more complex evolutionary history.
With this latter example in mind, it is worth noting that the present
7 gene locus in not invariant. A human haplotype dominant in
Papua New-Guinea is lacking the A3B gene, while others have
cogently argued for loss and gain of the A3H gene [62].
Interestingly, A3F and A3G are precisely the cytidine
deaminases that are most active on HIV-1Dvif in phenotypic
assays [5,6,8,46]. As the promoters are highly similar, it is
expected that their expression would be coordinated and hence
they could restrict HIV together, if given the chance. In this
context it is worth noting that not only A3F and A3G expression
was surprisingly coordinated, the two deaminases formed
heterodimers [8]. A3G exon 2 is homologous to exon 5 (Jarmuz).
In the recently reported crystal structures for the CCD2 domain of
A3G, exon 2 is part of a homodimerization interface (Harris &
Goodman). In view of the recombinant nature of A3G, this might
contribute to efficient A3F and A3G heterodimer formation.
Two New World monkey (NWM) sequences formally annotated
as A3Gs could well be A3F-G chimeras as they were generated by
screening genomes with the A3G sequence [50]. As it is a chimera,
blast searching alone might well generate a recombinant even
though the A3G of the genome in question might not have exons
1+2 akin to A3F. Both of these NWM sequences lack the singular
HPE motif in the CDD1 of all other A3Gs. While not definitive, it
urges caution. Three gibbon sequences annotated as A3G are
Figure 7. HIV-1Dvif editing by 6 A3 deaminases. A) 3DPCR of
cDNA harvested 18 h post-infection of CEMx174 cells. Virus stocks were
made using QT6 cells, white asterisks represent the PCR product cloned
and sequenced. B) Mutation statistics for the HIV-1 hypermutants.
doi:10.1371/journal.pone.0004277.g007
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Numbers at branching nodes are percentages of 1000 bootstrap replications - only bootstrap values .40 are given. A3H was excluded was excluded
from the exon 1 and 8 trees for lack of significant homology. A3B was excluded from the exon 1 tree because it is only 71 bases long and led to an
even less robust tree. Nonetheless, as it differs from the A3DE sequence by only 2 bases, it is shown in parentheses. The anomalous A3G sequences
are highlighted in red. Another case of possible recombination is highlighted in sky blue as the differing (3A-3, 3B-6, 3G-6) and (3A-4, 3G-7) 3B-7)
topologies are supported by strong bootstrap values. After gap stripping, the lengths of each alignment were as follows: exon 1, 89 bp; exons 2+5,
135 bp; exons 3+6, 256 bp; exons 4+7, 113 bp and exon 8, 240 bp.
doi:10.1371/journal.pone.0004277.g008
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genomic DNA while the break points map to exon boundaries
[63]. That three subspecies of gibbon ape each harbour a different
A3G chimera is not impossible, although parsimony suggests this
to be implausible.
Given the extensive gene conversion and near identity of some
exons, for example A3A-4 and A3G-7 (Figure 8), it is
understandable that computer programs are unable to always
identify correctly an APOBEC3 gene. The above examples are
not, unfortunately unique. For example, the Macaca mulatta entry
XM_001094452, ostensibly for A3G, actually encodes three
CDDs. By comparison with the human A3 sequences, it is trivial
to show that CDD1+2 are those of a bona fide macaque A3F gene
while the third domain corresponds to CDD2 of the macaque
A3G gene. The Macaca mulatta A3D entry XM_001094328
misidentifies the initiator methionine codon – as the coding region
of exon 1 is only 6 amino acid residues long, the program
presumably missed it. Consequently the A3D entry starts with a
conserved Met residue that is actually within the second exon of
the human orthologue. Equivalents for A3A and A3B are not
annotated in the macaque genome via a NCBI search although it
is trivial to find them with a Blast search. A few analogous errors
can be found among the annotated genomic chimpanzee A3
sequences.
Apart from these in silico issues, some rather mundane issues
come to the fore. Given the near identity of some exons across A3
deaminases, for example A3A exon 4 and A3G exon 7 or A3A
exon 3 and A3B exon 6, ambiguities may arise when probing
Northern and Southern blots with near-complete cDNAs. The
same goes for in situ RNA hybridization using complete cDNAs.
Polyclonal sera could possibly pick up more than one APOBEC3
protein. Depending on the region targeted, there is even the
chance that a monoclonal antibody might show a little cross-
reactivity.
The study shows that while six human APOBEC3 deaminases
can edit HBV albeit at low frequencies, the degree of nascent
cDNA editing can be as great as 90%. Recently the A3A, A3C and
A3H deaminases have been shown to be active against human
papillomavirus DNA in benign and pre-cancerous lesions [64].
Transcriptionally active HPV genomes are in the form of mini-
chromosomes complete with nucleosome [65]. If they are
vulnerable to cytidine deamination, say in a subset of cells with
over-expressed APOBEC3A/C/H, then it raises the intriguing
question as to how chromosomal DNA is protected from these
three nuclear APOBEC3 deaminases, which are, when given the
chance, hugely efficient at editing ssDNA in vivo and in vitro
(Figures 4 and 6).
Activation induced deaminase (AID), which is to all extents and
purposes a human APOBEC3 gene [64], albeit found at
ch12p13.31, can be specifically targeted to the IgV gene, although
the mechanism is not clear. However, there is an ample literature
demonstrating ectopic expression of AID in non-lymphoid tissues
such as stomach and liver in the case of chronic HCV associated
hepatitis [66–70]. Indeed, transgenic mice with AID under the
control of a hepatotropic promoter give rise to HCCs, paralleling
earlier findings for APOBEC1 transgenic mice [71,72]. While
efficient mutators, especially A3A, their effects are surely
countered by highly efficient DNA repair machinery and so it
may be extremely difficult to identify hyperedited human genes
precisely for this reason. From this perspective, hyperedited HBV
or dsDNA virus genomes could be seen as a surrogate marker for
these powerful mutators especially when associated with predis-
posing or pre-neoplastic lesions like cirrhosis and low and high-
grade intraepithelial lesions of the cervix.
Materials and Methods
Plasmids
Human A3A cDNA was obtained from Bryan Cullen, A3G
from Naveenan Navaratnam and A3DE from Michael Malim.
The remaining human APOBEC3 cDNAs were obtained from an
IMAGE clones cDNA library and were sub-cloned in the
pcDNA3.1D/V5-His-TOPO expression vector (Invitrogen) as
previously described [14]. Construction of A3Gn (N-terminal
region or CDD1) was obtained by deleting exons 5–7 from the
A3G clone, while A3Gc (C-terminal region or CDD2) was
obtained by deleting exons 2–4 (Figure 2A). Plasmid pCayw allows
expression of pre-genomic HBV RNA under control of the
powerful cytomegalovirus immediate early promoter (CMV-IE)
and was provided by Frank Chisari (Scripps Research Institute).
The HIV-1 infectious molecular clone pNL4.3 plasmid has
already described [73].
Cells, transfections and infections
Virus stocks were made following transfection of the quail
muscle fibroblast cell line QT6. Briefly, 10
5 QT6 cells were co-
transfected with equal amounts (2 mg) of the pCayw or pNL4.3
and A3 expression plasmids using FuGENE6 (Roche). In both
Figure 9. Colour coded representation of A3 coding exons. Colour denotes generally similar overall clustering and hides finer detail. Coding
regions are drawn to scale. As the iMet of A3H is within exon 2, exon1 is not shown. As it is not possible in an a posteriori analysis to distinguish
between recombination and rate heterogeneity, while some clusters are not supported by strong bootstrap values, the schematic should not be
overly interpreted.
doi:10.1371/journal.pone.0004277.g009
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treated with DNaseI (10 U/mL, 1 mM MgCl2, 1 h/37uC). HIV
virus stock was titrated with a p24 Elisa kit (PerkinElmer) and was
used to infect H9 cells for 18 h. Total DNA was extracted using
the MasterPure
TM complete DNA and RNA purification kit
(Epicentre). QT6 cells were maintained in HAM’s F40 medium,
supplemented with 1% chicken serum, 10% FCS, 5% tryptose
phosphate, 2 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml
streptomycin while H9 cells were maintained in DMEM medium
supplemented with 2 mM L-glutamine, 50 U/ml penicillin and
50 mg/ml streptomycin.
Immunofluorescence
HeLa cells were grown to a density of 5610
5 cells per dish and
transfected with 0.4 mg of pcDNA6-mAPOBEC using FuGENE 6
(Roche). After 48 hours, the cells were washed twice with PBS,
fixed for 45 minutes in a 50:50 methanol/ethanol mix. As primary
antibodies, a mouse monoclonal antibody specific for the V5
epitope tag (Invitrogen) was used at a 1:200 dilution for 1 hour at
37uC. Cells were washed twice with PBS, and fluoresceine
isothiocyanate-conjugated anti-mouse antibody was used as
second antibody (Sigma) at a dilution 1:200 for 30 minutes at
37uC. Cells were then washed three times in PBS, then incubated
with 0.1 mg/ml of 49,6 9-diamino-2-phenylindole (DAPI) for
10 min. at room temperature to counter stain nuclei. Immuno-
fluorescence was observed by microscopy (Zeiss).
PCR amplification, cloning and sequencing
All samples were digested with proteinase K (0.1 mg/ml,
Eurobio) in lysis buffer at 65uC for 15 min. Total nucleic acids
were extracted using the MasterPure
TM complete DNA and
RNA purification kit (Epicentre). A fragment just 59 to the
HBV X gene was chosen as described [14]. In order to
increase sensitivity and specificity, hot start PCR was
performed with primers 59HBVout and 39HBVout while
primers 59HBVin and 39H B V i nw e r eu s e df o rt h es e c o n d
round and were already described [14]. GRA hypermutated
genomes were recovered using differential DNA denaturation
PCR (3DPCR) in a two round procedure [40]. The first
reaction involved standard amplification, the reaction param-
eters were 95uC for 5 min., followed by 35 cycles (95uCf o r
30 s., 50uC for 30 s., and 72uC for 1 min.) and finally for
10 min. at 72uC for the first round. Differential amplification
occurred in the second round using the equivalent of 0.2 mLo f
the first round reaction as input. Differential amplification was
performed by using an Eppendorf gradient Mastercycler S
programmed to generate a 4–12uC gradient in the denatur-
ation temperature. Gradient cycling conditions were, from
93uCt o8 1 uC for 5 min., followed by 35 cycles (93–81uCf o r
30 s., 50uC for 30 s., and 72uC for 1 min.) and finally 10 min.
at 72uC. First round PCR gave a 294 bp product, while second
r o u n dP C Ry i e l d e da2 1 3b pf r a g m e n t .
The HIV-1 env V1V2 region was amplified by a 3DPCR
procedure, the first reaction PCR was amplified using primers
SK122out 59 TACCCACARACCCCAACCCACAA and
SK123out, 59 TTTTAGAATYGYAAAAYYAG (R=A, G and
Y=C, T). Parameters were 95uC for 5 min., followed by 35 cycles
(95uC for 30 s., 50uC for 30 s., and 72uC for 1 min.) and finally for
10 min. at 72uC. Selective 3DPCR was performed at the second
round using primers SK122/Rin 54 AAARCCTAAARC-
CATRTRTA and SK123/Yin 59 TAATGTATGGGAATTG-
GYTTAA with the following conditions: 77uCt o8 3 uC for 5 min.,
followed by 35 cycles (77–83uC for 30 s., 50uC for 30 s., and 72uC
for 1 min.) and finally for 10 min. at 72uC. The last PCR product
yielded a 304 bp fragment. PCR products were purified from
agarose gels (Qiaex II kit, Qiagen, France) and ligated into the
TOPO TA cloning vector (Invitrogen, France). After transforma-
tion of Top10 Blue cells, up to 40 clones were picked. Sequencing
was performed using BigDye Terminator V1.1 (Applied Biosys-
tems).
Primers used for the construction of A3Gn plasmid were E1 and
E4 respectively 59 CACCATGAAGCCTCACTTCAGAAACA
and 59 GTTTTCCTGATTTCTGAGAATCTCCCCCAGCAT-
GAT where the initiator methionine codon is underlined, while for
A3Gc plasmid construction primers used were E5 and E8
respectively, 59 CACCATGAAGCCTCACTTCAGACACTC-
GATGGATCCACCCA and 59 CCATTCTCCAGAATCAG-
GAAAAC. The buffer conditions for amplifications were 2.5 mM
MgCl2, 50 mM KCl, 10 mM Tris-HCl pH 8.3, 200 mM of each
dNTP, 100 mM of each primer, and 2.5 units of Pfu polymerase
(Promega) in a final volume of 50 mL. PCR conditions were: 95uC
for 5 min., followed by 20 cycles (95uC for 30 s., 55uC for 30 s.,
and 72uC for 30 s.) and finally for 10 min. at 72uC. PCR product
was purified and cloned in pcDNA3.1D/V5-His-TOPO.
Phylogenic analyses
The APOBEC3 sequences used in the alignment were: A3A
NM_145699; A3B NM_004900; A3C NM_014508; A3DE
NM_152426; A3F NM_001006666; A3G NM_021822; and
A3H NM_181773. All sequences were aligned using CLUSTALX
[74]. Trees were constructed by the Neighbor-Joining method in
MEGA (Version 3.1) [75].
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